2158 (2158) Fair Value & Analysis

Healthcare · Market cap HK$5.0B

2 2158 2158 · HK

PriceHK$4.87

Fair ValueHK$1.83

Upside-62.4%

Quality46/100

Watch 2158 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$1.28 – HK$1.83

Fair value as of: Jul 2, 2026

From 9 valuation models · updated today

Share price −12.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$4.36 – HK$7.14 · fair‑value band HK$1.28 – HK$1.83 · the HK$4.87 price screens above the HK$1.83 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2158 (2158) currently trades at HK$4.87, while our model-based Fair Value estimate is HK$1.83 — implying the stock looks roughly 62.4% overvalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 2158 generated revenue of HK$819M at a net margin of 8.9%. Revenue grew 19.6% year over year. It earns a return on equity of 2.1%. The balance sheet holds a net cash position of HK$596M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$819M

Revenue growth (YoY) +19.6%

Net margin 8.9%

Return on equity 2.1%

Free cash flow −HK$351M FY2025

P/E ratio 60.9

More key figures

Operating margin 41.7%

EPS (TTM) HK$-0.0800

Net cash HK$596M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

2158 reported revenue of HK$791M in FY2026 versus HK$1.2B in FY2022, a compound −10.6%/yr. Reported net income was HK$70.2M in FY2026.

Revenue −10.6%/yr

FY22 HK$1.2B

FY23 HK$805M

FY24 HK$807M

FY25 HK$715M

FY26 HK$791M

Net income

FY22 −HK$762M

FY23 −HK$628M

FY24 −HK$195M

FY25 −HK$118M

FY26 HK$70.2M

Is 2158 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$172.61	$104.16	-40%
Pro Medicus Limited PME	A$161.58	A$33.82	-79%
BrightSpring Health Services, Inc BTSG	$67.20	$26.39	-61%
Tempus AI, Inc TEM	$48.61	$12.67	-74%
HealthEquity, Inc HQY	$86.03	$54.47	-37%
M3, Inc MTHRY	$5.20	$5.32	+2%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2158 (2158) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$1.83 versus a price of HK$4.87 — about −62% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2158?

Our model-based fair value for 2158 is HK$1.83 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$4.87.

What is the quality score of 2158?

2158 has a Quality Score of 46/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2158 (2158)?

2158 reported trailing-twelve-month revenue of about HK$819M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2158?

The net profit margin of 2158 is about 8.9%, meaning it keeps roughly 8.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.